53 related articles for article (PubMed ID: 34863647)
1. Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system.
Mutoh Y; Umemura T; Ota A; Okuda K; Moriya R; Tago M; Soejima K; Noguchi Y; Bando T; Ota S; Sato T; Hirota S; Hagimoto S; Takei R; Sasano H; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Ichihara T; Kondoh Y
J Infect Chemother; 2022 Feb; 28(2):352-355. PubMed ID: 34863647
[TBL] [Abstract][Full Text] [Related]
2. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of neutralizing antibody cocktail in hemodialysis patients: a case series of 20 patients treated with or without REGN-COV2.
Arikawa S; Fukuoka K; Nakamoto K; Kunitomo R; Matsuno Y; Shimazaki T; Saraya T; Kawakami T; Kishimoto M; Komagata Y; Kurai D; Ishi H; Kaname S
Clin Exp Nephrol; 2022 May; 26(5):476-485. PubMed ID: 35182277
[TBL] [Abstract][Full Text] [Related]
4. Combined REGN-COV2 Antibody Therapy Immediately Prevented a Patient with Refractory Type 1 Autoimmune Pancreatitis from Contracting SARS-CoV-2 during the Sixth Wave in Japan.
Katsuo C; Kubota K; Tanaka K; Kurita Y; Nakajima A
Intern Med; 2023; 62(12):1765-1770. PubMed ID: 37316279
[TBL] [Abstract][Full Text] [Related]
5. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS
Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy in COVID-19.
Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
[TBL] [Abstract][Full Text] [Related]
8. [SARS-CoV-2 neutralizing monoclonal antibodies: a potential breakthrough in the early treatment of Covid-19 in high-risk patients].
de Bree GJ; Wiersinga WJ
Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854645
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.
Bruzzesi E; Ranzenigo M; Castagna A; Spagnuolo V
New Microbiol; 2021 Jul; 44(3):135-144. PubMed ID: 34783348
[TBL] [Abstract][Full Text] [Related]
10. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
Halwe S; Kupke A; Vanshylla K; Liberta F; Gruell H; Zehner M; Rohde C; Krähling V; Gellhorn Serra M; Kreer C; Klüver M; Sauerhering L; Schmidt J; Cai Z; Han F; Young D; Yang G; Widera M; Koch M; Werner A; Kämper L; Becker N; Marlow MS; Eickmann M; Ciesek S; Schiele F; Klein F; Becker S
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452363
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
Lai R; Zhou T; Xiang X; Lu J; Xin H; Xie Q
Front Med; 2021 Aug; 15(4):644-648. PubMed ID: 33909259
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
13. In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d.
Lau D; Saxinger L
Ann Intern Med; 2022 Jan; 175(1):JC5. PubMed ID: 34978854
[TBL] [Abstract][Full Text] [Related]
14. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
[TBL] [Abstract][Full Text] [Related]
15. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
[TBL] [Abstract][Full Text] [Related]
16. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
[TBL] [Abstract][Full Text] [Related]
17. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
18. Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.
Fenaux H; Gueneau R; Chaghouri A; Henry B; Mouna L; Roque-Afonso AM; Vauloup-Fellous C
BMC Infect Dis; 2021 Dec; 21(1):1223. PubMed ID: 34876033
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
[TBL] [Abstract][Full Text] [Related]
20. Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities.
Walker VL; Meyer A; Paauw D; Arend M
J Am Med Dir Assoc; 2022 Jan; 23(1):141-145. PubMed ID: 34890559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
